ImmunityBio, Inc. (IBRX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
ImmunityBio’s revenue went from $44000 in fiscal 2016 to $113M in fiscal 2025, growth of about 139.3% a year.
Net income in fiscal 2025 was -$351M, a net margin of -310.2%; the best year in this period was 2018 with -$96M.
Over the twelve months to September 30, 2026, revenue was $183M and net income -$1.1B.
Free cash flow was -$309M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 1022% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $183M | $113M | $15M | $622000 | $240000 | $934000 | $605000 | $2M | $47000 | $45000 | $44000 |
| Gross profit | $180M | $113M | $15M | $622000 | $240000 | — | — | — | — | — | — |
| Operating income | -$274M | -$256M | -$344M | -$362M | -$351M | -$330M | -$221M | -$156M | -$98M | -$99M | -$124M |
| Net income | -$1.1B | -$351M | -$414M | -$583M | -$417M | -$347M | -$222M | -$158M | -$96M | -$96M | -$121M |
| EPS (diluted) | $-1.08 | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 | $-0.59 | $-0.43 | $-1.22 | $-1.20 | $-1.47 |
| R&D | — | — | $190M | $232M | $248M | $196M | $140M | $112M | $56M | $42M | $29M |
| Revenue growth | — | +668.3% | +2270.6% | +159.2% | −74.3% | +54.4% | −72.5% | +4585.1% | +4.4% | +2.3% | −81.4% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$288M | -$305M | -$391M | -$367M | -$338M | -$274M | -$172M | -$152M | -$63M | -$49M | -$39M |
| Capital spending | -$9M | -$4M | -$7M | -$31M | -$78M | -$34M | -$2M | -$4M | -$13M | -$35M | -$7M |
| Free cash flow | -$297M | -$309M | -$398M | -$397M | -$416M | -$308M | -$173M | -$156M | -$76M | -$84M | -$45M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | $0 | $0 | $3M | $228000 | $15M | $16M |
| Stock-based pay | $34M | $37M | $34M | $49M | $40M | $57M | $2M | $3M | $23M | $37M | $74M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $243M | $150M | $266M | $107M | $317M | $96M | $112M | $74M | $128M | $199M |
| Debt | — | $367M | $328M | $201M | $483M | $40M | $15M | $14M | — | — | — |
| Equity | — | -$500M | -$489M | -$587M | -$447M | -$242M | -$120M | $121M | $146M | $219M | $293M |
| Total assets | — | $502M | $383M | $504M | $362M | $469M | $221M | $143M | $182M | $250M | $317M |
| Shares (diluted) | 1.06B | 920M | 700M | 509M | 400M | 389M | 377M | 366M | 79M | 81M | 82M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 98.8% | 99.3% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| Operating margin | -150.2% | -226.0% | -2334.2% | -58239.5% | -146400.0% | -35361.9% | -36509.1% | -7095.9% | -209300.0% | -220300.0% | -283000.0% |
| Net margin | -607.8% | -310.2% | -2804.8% | -93761.4% | -173600.0% | -37129.6% | -36669.6% | -7165.2% | -204700.0% | -214300.0% | -274600.0% |
| FCF margin | -162.5% | -272.6% | -2700.1% | -63881.2% | -173200.0% | -32974.5% | -28660.0% | -7102.5% | -162700.0% | -185800.0% | -102600.0% |
| ROIC | — | — | — | — | -789.0% | — | — | -115.9% | -67.0% | -45.1% | -42.2% |
| ROE | — | 70.2% | 84.6% | 99.4% | 93.1% | 143.2% | 185.2% | -130.7% | -65.9% | -44.1% | -41.2% |
Frequently asked questions
What is ImmunityBio’s annual revenue?
$113M in fiscal 2025 and $183M over the twelve months to September 30, 2026.
How much profit does ImmunityBio make?
Net income was -$351M in fiscal 2025 (net margin -310.2%).
Is ImmunityBio’s revenue growing?
Yes: revenue rose 668.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.